Stuart Seropian

Stuart Seropian, MD is a Professor of Internal Medicine (Hematology) at Yale School of Medicine and holds multiple leadership roles including Interim Director of the Stem Cell Transplant Program, Co-Director of CAR T-Cell Therapy, and Chairman of the Car-T Cell Joint Steering Committee at Yale-New Haven Hospital. He specializes in blood cancers such as leukemia, lymphoma, and multiple myeloma, with a focus on improving transplantation outcomes and novel anti-cancer therapies. Dr. Seropian completed his medical degree at George Washington University and residency/fellowship training at Yale-New Haven Hospital.

Education:

• BS, Tufts University (1984)
• MD, George Washington University School of Medicine (1991)
• Residency and Fellowship, Yale-New Haven Hospital/Yale University School of Medicine (1996)

Research Interests: Dr. Seropian's work centers on advancing hematologic malignancy treatments, including:

• Optimizing allogeneic stem cell transplantation protocols
• Developing targeted therapies like CAR T-cell and radioimmunotherapy
• Managing graft-versus-host disease
• Evaluating cost-effectiveness of novel therapies
• Improving outcomes in relapsed/refractory AML and lymphomas

Clinical Trials: Leads/co-investigates studies in:

• CAR T-cell therapy for B-cell lymphomas
• Radioimmunotherapy (e.g., 131I-Apamistamab) for AML
• Combination therapies for multiple myeloma
• Phase III trials for targeted conditioning regimens

Awards:

• Yale Cancer Center Clinical Excellence Award (2016)
• David S. Fischer Teaching Award (2014)
• Alpha Omega Alpha Honor Society (1991)

Labs/Teams: Active in Yale’s Hematologic Malignancies Program, Cellular Therapies Program, and Stem Cell Transplantation team. Collaborates with industry partners on translational research.